BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32749654)

  • 1. Thyrotropin receptor antibodies and Graves' orbitopathy.
    Diana T; Ponto KA; Kahaly GJ
    J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.
    Sarić Matutinović M; Diana T; Nedeljković Beleslin B; Ćirić J; Žarković M; Kahaly GJ; Ignjatović S
    J Endocrinol Invest; 2022 Jan; 45(1):189-197. PubMed ID: 34324163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation.
    Allelein S; Diana T; Ehlers M; Kanitz M; Hermsen D; Schott M; Kahaly GJ
    Horm Metab Res; 2019 Jun; 51(6):341-346. PubMed ID: 31207654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
    Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
    J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.
    Kahaly GJ; Wüster C; Olivo PD; Diana T
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2561-2568. PubMed ID: 30753531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
    van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phenotype of Graves' orbitopathy is associated with thyrotropin receptor antibody levels.
    Sarić Matutinović M; Kahaly GJ; Žarković M; Ćirić J; Ignjatović S; Nedeljković Beleslin B
    J Endocrinol Invest; 2023 Nov; 46(11):2309-2317. PubMed ID: 37020104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
    Krieger CC; Kahaly GJ; Azam A; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
    Thyroid; 2022 Jan; 32(1):90-96. PubMed ID: 34714162
    [No Abstract]   [Full Text] [Related]  

  • 9. Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.
    Kahaly GJ; Diana T; Kanitz M; Frommer L; Olivo PD
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1006-14. PubMed ID: 31865369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.
    Kahaly GJ; Diana T; Olivo PD
    Endocr Pract; 2020 Jan; 26(1):97-106. PubMed ID: 32022598
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
    Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
    Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
    Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
    Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
    [No Abstract]   [Full Text] [Related]  

  • 14. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
    McLachlan SM; Rapoport B
    Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
    Krieger CC; Neumann S; Gershengorn MC
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
    Lenzner C; Morgenthaler NG
    Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease.
    Masetti G; Moshkelgosha S; Köhling HL; Covelli D; Banga JP; Berchner-Pfannschmidt U; Horstmann M; Diaz-Cano S; Goertz GE; Plummer S; Eckstein A; Ludgate M; Biscarini F; Marchesi JR;
    Microbiome; 2018 May; 6(1):97. PubMed ID: 29801507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
    Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
    Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between thyrotropin receptor antibody bioactivity and inhibition of 125I-bovine thyrotropin binding.
    Wallaschofski H; Kaczmarek M; Miehle K; Hentschel B; Paschke R
    Thyroid; 2000 Oct; 10(10):897-907. PubMed ID: 11081256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
    Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
    Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.